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ABSTRACT
The advances in the treatment of melanoma patients with V600 mutations in the BRAF gene over the past few 
years result from the introduction of targeted drugs and modern immunotherapy. Unfortunately, at the moment 
there is a lack of data from a randomised clinical trial that determines the optimal sequence of anti-BRAF/anti-MEK 
drugs and immunotherapy in BRAF (+) patients. This paper discusses the most important clinical trials performed 
so far, the results of which may be helpful in the selection of systemic treatment in patients with advanced or 
metastatic melanoma harbouring BRAF V600 mutation. Formal analysis indicates that molecularly targeted treat-
ment is the method of choice in the first-line setting in patients with BRAF (+) melanoma because the value of 
anti-BRAF/anti-MEK drugs in this population was confirmed by consistent results of three phase 3 studies. Con-
versely, evidence for the effectiveness of immunotherapy in advanced BRAF (+) melanoma are much weaker. 
However, both methods significantly improved the prognosis, and in some patients with BRAF gene mutation they 
led to long-term survival. Currently, the research is ongoing, and the results may resolve this issue.
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Introduction
For many years, the results of treatment of patients 
with advanced melanoma were unsatisfactory. Median 
survival time was only six months, and only about 25% 
of patients survived a year despite the use of chemo-
therapy. The situation has been significantly changed 
in the last five years, since several new medicines were 
registered which markedly improved the prognosis. This 
progress also applies to melanoma patients with the 
BRAF V600 mutation, known to be associated with 
shorter overall survival (OS); in this case it results from 
introduction of targeted drugs and modern immuno-
therapy [1, 2].
Targeted therapy anti-BRAF
The discovery of the importance of BRAF V600-ac-
tivating mutations, occurring in about 50% of patients 
with advanced melanoma, as well as the associated acti-
vation of the MAPK pathway (RAS/RAF/MEK/ERK), 
allowed the development of small molecule inhibitors 
of BRAF serine-threonine kinase, dabrafenib, and 
vemurafenib [1, 3]. Despite the high antitumor activity 
measured by objective response rate (ORR), resist-
ance developed relatively rapidly during the use of 
both drugs, which was, among other things, related to 
reactivation of the MAPK pathway. The occurrence of 
resistance limited the effectiveness of treatment, and 
median progression-free survival (PFS) did not exceed 
6–7 months. Only the combination of BRAF inhibitor 
with an anti-MEK drug (cobimetinib or trametinib) 
resulted in further improvement of treatment results 
— an increase of ORR (by 14–20%), median PFS (about 
2–5 months), and median OS (about 5–8 months) as well 
as a reduction in the incidence of anti-BRAF-induced 
skin tumours [1, 3–6]. 
All three studies evaluating the use of BRAF inhibi-
tor in combination with MEK inhibitor in previously un-
treated BRAF (+) patients: coBRIM (comparing the use 
of cobimetinib and vemurafenib with vemurafenib) [4]; 
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Table 1. Effects of combined anti-BRAF/anti-MEK therapy in experimental groups in phase 3 trials [3–6]
coBRIM COMBI-d COMBI-v
Objective response rates (%) 70 69 64
Median PFS (months) 12.3 11 12.6
Median OS (months) 22.3 25.1 25.6
PFS — progression-free survival; OS — overall survival
COMBI-d (dabrafenib and trametinib with dabrafenib 
alone) [5]; and COMBI-v (dabrafenib and trametinib 
with vemurafenib) [6] confirmed the superiority of 
anti-BRAF and anti-MEK therapy over anti-BRAF 
monotherapy (Table 1). Slightly shorter median OS 
observed in the coBRIM study may be associated with 
a higher percentage (44% vs. 34–36%) of patients with 
initially elevated LDH, which is a strong unfavourable 
prognostic factor in advanced melanoma. Despite the 
lack of direct comparison of both combined therapies 
(dabrafenib with trametinib versus cobimetinib with 
vemurafenib), consistency of results and indirect analysis 
indicate comparable activity and effectiveness of both 
treatment regimens [3–6]. 
Immunotherapy
Currently, immunotherapy also has a basic role in 
the treatment of patients with advanced melanoma, by 
targeting immune checkpoints. Ipilimumab was the first 
antibody that, by binding CTLA-4 antigen (cytotoxic 
T cell antigen 4), enhanced the T-cell-dependent an-
titumour response and resulted in prolonged survival 
of melanoma patients. In a study comparing the use 
of ipilimumab in combination with dacarbazine with 
dacarbazine with placebo, in previously untreated 
patients with advanced melanoma, the median OS was 
11.2 vs. 9.1 months, respectively, and three-year survival 
reached 20.8% vs. 12.2% [7].
Significantly lower toxicity and greater efficacy were 
observed after the use of drugs blocking PD-1 receptor 
(programmed death 1) and its ligand PD-L1. The pivotal 
studies regarding the use of nivolumab (anti-PD-1 mono-
clonal antibody) were CheckMate 037 [8, 9], CheckMate 
066 [10], and CheckMate 067 [11, 12], whereas Keynote 
006 was the key study for pembrolizumab [13, 14]. 
The CheckMate 037 study recruited patients with 
(22%) or without BRAF mutation, who had pre viously 
received ipilimumab (BRAF [+] patients — also 
anti-BRAF drug). Patients received nivolumab or 
chemotherapy with dacarbazine or carboplatin and 
paclitaxel (investigator’s choice). There was no diffe-
rence in OS (median — 15.7 vs. 14.4 months) and PFS 
(median — 3.1 vs. 3.7 months), which could result from 
minor differences in baseline characteristics of the study 
groups — slightly more patients (20% vs. 14%) in the 
experimental group had metastases in the central ner-
vous system (CNS) and increased lactate dehydrogenase 
(LDH) level — 52% vs. 38%. Further treatments (an-
ti-PD-1 therapy given on progression) also differed be-
tween the arms — 11% vs. 41%. However, the response 
rate and median duration of response were significantly 
higher in the group receiving nivolumab — 27% vs. 10% 
and 32 vs. 13 months, respectively [1, 8, 9].
Another two studies looked at the use of nivolumab 
in previously untreated patients with unresectable or 
disseminated melanoma. In the CheckMate 066 study 
dacarbazine was a comparator and the primary end-
point was OS. The study did not include patients with 
the BRAF mutation and, similarly to CheckMate 037, 
with symptomatic metastases in CNS. As in the pre-
vious study, the response rate in the group receiving 
nivolumab was higher than in the chemotherapy group 
(40% vs. 13.9%). In addition, the median PFS was sig-
nificantly higher (5.1 vs. 2.2 months), and the percent-
age of patients who survived one year was significantly 
higher (72.9% vs. 42.1%, with 58% reduction in risk of 
death). At the time of publication of the study results, 
OS was not achieved in the nivolumab group, while it 
was 10.8 months in the control group [10].
The CheckMate 067 study included BRAF (+) pa-
tients (32% of the study population) and had PFS and 
OS as co-primary endpoints. In this study, previously 
untreated patients with unresectable melanoma at stage 
III or IV received nivolumab monotherapy, nivolumab 
in combination with ipilimumab, or ipilimumab mono-
therapy. The median PFS was 11.5 vs. 6.9 vs. 2.9 months, 
respectively. After a minimum of 36 months of obser-
vation, the median OS was not reached in patients 
receiving nivolumab in combination with ipilimumab; 
it was 37.6 months for nivolumab and 19.9 months for 
ipilimumab. The three-year survival rate was 58% for 
patients in the first group, 52% in the second group, and 
34% in the ipilimumab arm [11, 12].
The Keynote 006 study compared pembrolizumab 
and ipilimumab in patients with inoperable or metastatic 
melanoma, who had not previous systemic treatment or 
received only one treatment line. BRAF mutations oc-
curred in 35% of patients treated with pembrolizumab, 
half of whom received prior anti-BRAF/anti-MEK 
therapy. The co-primary endpoints were PFS and OS. 
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During the follow-up of 23 months, median OS was not 
reached in pembrolizumab-treated patients (for ipili-
mumab — 16 months), and the two-year survival rate in 
patients treated with pembrolizumab was 55% [13, 14].
In all studies objective response rates (31–44%) and 
median PFS (about 5–7 months in the groups receiving 
nivolumab and pembrolizumab monotherapy) were 
slightly lower as compared with anti-BRAF/anti-MEK 
therapy [1]. Some patients, however, had a long-term 
clinical benefit. In general, 52% of patients treated with 
nivolumab in the Checkmate 067 study survived three 
years, and 55% of patients treated with pembrolizumab 
in the Keynote 006 study survived 24 months [12, 14]. 
The time from treatment initiation to response was 
longer than for anti-BRAF/anti-MEK therapy. For 
nivolumab-treated patients it ranged in various stud-
ies between 1.2 and 12.5 months (median approx. 
2.2–2.78 months) [9, 11]. The combination of nivolumab 
with ipilimumab resulted in a further improvement in 
PFS (median 11.5 months) and objective response rates 
(58%), approaching the results obtained with the use of 
anti-BRAF/anti-MEK therapy, although at the expense 
of significantly higher toxicity than anti-PD-1 mono-
therapy. Median time to response to combined treat-
ment was comparable (2.8 months), and the duration 
of response ranged between 1.1 and 11.6 months [11]. 
In the Checkmate 037 study the response rate to 
nivolumab in BRAF (+) patients was numerically lower 
than in BRAF (–) patients (23% vs. 34%) [8]. Similarly, 
in the Checkmate 067 study the three-year PFS rate 
in patients treated with nivolumab was lower (22% 
vs. 36%), as was median PFS (5.6 vs. 7.9 months) in 
BRAF (+) patients compared to BRAF (–). In the case 
of combined nivolumab and ipilimumab the median PFS 
had a similar value (11.7 vs. 11.2 months, respectively), 
and overall survival rate after three years was slightly 
higher in the BRAF group (+) (68% vs. 53%), which 
might suggest that anti-PD-1 monotherapy in BRAF 
(+) patients is less effective than the combination of 
nivolumab and ipilimumab [12].
While in previously untreated patients with inoper-
able or metastatic melanoma and no BRAF mutation 
the treatment of choice is immunotherapy, in the case 
of patients with BRAF V600 mutation, besides immu-
notherapy, we also have anti-BRAF/anti-MEK targeted 
treatment with effectiveness confirmed by the results of 
phase III clinical trials involving this population.
Sequential therapy
A very important question regards sequential use 
of anti-BRAF/anti-MEK drugs or immunotherapy 
and selection of patients in whom the initiation of 
a specific treatment would be of greater clinical ben-
efit. Unfortunately, we do not know the answer to 
the question about the optimal treatment sequence 
in BRAF (+) patients. There are no data from ran-
domised clinical trials that would directly compare 
targeted therapy and immunotherapy in previously 
untreated patients or determine the best sequence of 
therapies. The majority of studies with immunothera-
py have involved a mixed population in which patients 
with BRAF mutations accounted for no more than 
35% [13] or — as in the Checkmate 066 study — BRAF 
gene mutation was an exclusion criterion [10]. In addi-
tion, while studies on anti-BRAF/anti-MEK therapies 
have been conducted in a previously untreated popu-
lation, studies with immunotherapy included patients 
receiving the first line of treatment or previously 
undergoing immunotherapy or anti-BRAF therapy. 
Sometimes, previous use of anti-BRAF/anti-MEK 
therapy was obligatory.
The above-mentioned circumstances mean that pa-
tient populations participating in clinical studies are di-
verse and it is difficult to draw conclusions about the su-
periority of one of the methods or the optimal treatment 
sequence based on the obtained results. Undoubtedly, 
the formal degree of reliability of scientific evidence 
supports the use of anti-BRAF/anti-MEK therapy.
Several retrospective analyses were published, 
mostly in small groups of patients (n = 34, 25, and 274), 
aiming to determine the optimal treatment sequence 
for BRAF (+) patients. It should be emphasised that 
a serious limitation of these analyses is the probable and 
difficult to control selection bias. Due to higher direct 
activity of anti-BRAF agents in patients with BRAF (+) 
disease patients who were qualified for immunotherapy 
instead of anti-BRAF treatment could have better prog-
nosis resulting from less rapid progression and smaller 
tumour volume or less frequent critical internal organ 
involvement. The conclusions from these observations 
indicated that in the case of use of anti-BRAF treatment 
in the first-line setting a larger number of patients did 
not receive or were unable to complete the planned 
second-line therapy due to rapid disease progression. 
Nevertheless, one- and two-year survival rates assessed 
in one of these studies did not differ significantly and 
amounted to 80% vs. 89% and 67% vs. 51% (p = 0.97) 
for targeted therapy followed by immunotherapy and 
for the reverse sequence, respectively. However, these 
observations come from an era before anti-PD-1 and 
anti-MEK therapy [15–17].
The more recent retrospective study, evaluating 
immunotherapy with the use of anti-PD-1 drugs, sug-
gests better results when immunotherapy is being used 
upfront. One of the conclusions was the observation 
that patients with a longer duration of response to 
anti-BRAF treatment (> 6 months) also had a greater 
benefit from anti-PD-1 treatment in the second-line, as 
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compared to patients with progression occurring during 
less than the first six months of treatment (34% vs. 15%, 
p = 0.04) [18].
One of the arguments supporting the superiority of 
immunotherapy in first-line treatment is information 
about long-term responses in some patients undergo-
ing immunotherapy compared to fast-growing resist-
ance to anti-BRAF/anti-MEK therapy (median PFS 
approx. 12 months). However, long-term responses 
are also observed in anti-BRAF/anti-MEK therapy. 
Recently published results of 36-month follow-up in 
the COMBI-d study showed that 19% of patients in 
the combined arm were being still treated at this time 
point [1, 3, 5]. In contrast to targeted treatment, im-
munotherapy is characterised in phase 3 clinical studies 
by lower objective response rates ranging between ap-
prox. 30% (monotherapy) and approx. 60% (combined 
use of nivolumab or pembrolizumab and ipilimumab) 
compared to about 70% for anti-BRAF/anti-MEK 
drugs. Median PFS achieved during immunotherapy 
(4–7 months for monotherapy and 11.5 months for the 
combined use of nivolumab and ipilimumab) also ap-
pears to be slightly lower than for anti-BRAF/anti-MEK 
therapy (11–12 months). However, both treatment strat-
egies give the patients long-term survival and — with an 
indirect comparison — a similar median OS [1, 4–14].
Information that to some extent could help to draw 
conclusions about the right sequence of treatment would 
be a comparison of objective response rates obtained 
in second-line treatment. In the two observational 
studies mentioned above, it was found that previous 
immunotherapy had no effect on the response rate 
obtained with anti-BRAF therapy [16, 17]. Regarding 
use of immunotherapy after anti-BRAF treatment, in 
one retrospective study more responses were found 
compared to the immunotherapy used in the first-line 
setting [17]. However, in a combined analysis of results 
of treatment with nivolumab in BRAF (+) and BRAF (–) 
patients it was found that the earlier use of anti-BRAF 
drugs and ipilimumab did not affect the response 
rate, and the duration of response was similar in both 
groups [1, 19]. In turn, the results of Keynote 006 study 
with pembrolizumab suggest that immunotherapy 
results may be worse in patients previously receiving 
anti-BRAF/anti-MEK therapy; the response rate for 
immunotherapy in the BRAF (+) population was 41% 
in previously untreated patients compared to 22% in 
patients previously receiving anti-BRAF treatment [1, 
13, 14]. Similar results were observed in a phase 2 study 
in patients with metastases in CNS, who had not un-
dergone immunotherapy before. The response rate to 
combined treatment with nivolumab and ipilimumab 
was 50% in the previously untreated population, while 
in patients receiving anti-BRAF therapy it was only 16%. 
Undoubtedly, the data presented — partly discrepant 
— do not allow us to draw unambiguous and reliable 
conclusions [20].
Time to response to immunotherapy with one drug 
ranged in various studies between 1.2 months and even 
12.5 months with a median of 8–12 weeks [9, 11, 19]. 
Besides this, the fact that only asymptomatic or oligo-
symptomatic patients with no CNS metastatic disease 
were qualified in some immunotherapy studies meant 
that anti-BRAF/anti-MEK therapy was often preferred 
in patients with severe symptoms, with elevated baseline 
LDH activity or metastases in critical organs due to the 
rapidly obtained objective response (median about six 
weeks for anti-BRAF monotherapy), sometimes even 
within a few days of starting treatment [4–6]. However, 
the intuitive belief in the legitimacy of using immunother-
apy in the first-line setting in patients without significant 
symptoms, normal LDH level, and low volume of cancer 
lesions, while the use of anti-BRAF therapy in those with 
more disease lesions, more severe accompanying symp-
toms, and high LDH activity, seems not to have sufficient 
evidence. Firstly, in studies using anti-BRAF/anti-MEK 
therapy in subgroups of patients with initially normal 
LDH activity, very good results were obtained — 48–56% 
of patients lived for at least three years (in the subset also 
having metastases in less than three locations — even 
approximately two-thirds of patients) [1, 4–6]. Secondly, 
the results of the Checkmate 067 study indicated that 
a combination of nivolumab with ipilimumab is also ef-
fective in patients with elevated LDH activity and more 
advanced disease and may produce a therapeutic effect 
even about a month from the start of treatment. The 
three-year survival rate among patients with elevated 
LDH activity undergoing anti-BRAF treatment was 
20–25%, and for immunotherapy with nivolumab with 
ipilimumab (when LDH > 2 × upper limit of normal) 
it reached 31% [11, 12].
Although expression of PD-L1, until recently, ap-
peared to be a natural predictive marker of response to 
anti-PD-1/PD-L1 therapy, the benefits of treatment have 
also been observed in patients without PD-L1 expres-
sion, which makes this biomarker not useful in clinical 
practice for better patient selection. Likewise, no ad-
ditional biomarkers could be established allowing more 
effective selection of the group of patients benefiting 
from anti-BRAF/anti-MEK therapy [1].
The frequency of adverse events grade 3–4 was 
significantly lower during single-agent immunotherapy 
(ipilimumab — 10–15%, nivolumab — 12%, pem-
brolizumab — 12%) than in patients receiving an-
ti-BRAF/anti-MEK combination therapy (48–60%) [1, 
3–14]. Although life-threatening complications were 
also observed during immunotherapy (e.g. interstitial 
pneumonitis), they were mostly reversible or manage-
able with glucocorticosteroids. However, combination 
immunotherapy (nivolumab with ipilimumab) was 
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characterised by a similar frequency of side effects to 
targeted therapy (59%) and a higher percentage of 
patients who were discontinued due to toxicity (39% 
vs. 11–16%) [11, 12].
Summary
Formal analysis of clinical trial results indicates that 
targeted therapy is a method of choice in the first-line 
treatment in patients with advanced BRAF (+) mela-
noma because the value of anti-BRAF/anti-MEK drugs 
in this population was confirmed by consistent results 
of different phase 3 studies. Immunotherapy has much 
less formal evidence of efficacy in this group of pa-
tients. Patients with BRAF mutations were a minority 
in immunotherapy studies, and the comparator was not 
an anti-BRAF/anti-MEK drug. However, both targeted 
therapy and immunotherapy significantly improved the 
prognosis, and in some patients harbouring BRAF muta-
tions it led to long-term survival. 
The issue of optimal choice of treatment for patients 
with inoperable or disseminated melanoma with BRAF 
V600 mutation remains unresolved to some extent. 
There are currently ongoing studies that aim to indi-
cate the optimal sequence of treatment in BRAF (+) 
patients: anti-BRAF/anti-MEK therapy, followed by 
immunotherapy or vice versa, as well as the combina-
tion of anti-PD1 and anti-BRAF/anti-MEK therapy. An 
example of such trials is a phase 3 study (NCT02224781) 
led by the US National Cancer Institute. Its primary 
endpoint is to assess whether, in previously untreated 
patients with unresectable stage III or IV melanoma 
and BRAF mutation, the use of anti-BRAF/anti-MEK 
treatment sequence followed by ipilimumab/nivolumab 
after disease progression, or vice versa, will lead to 
a higher two-year survival rate. In addition, evaluation of 
response rate, PFS, and treatment tolerance is planned 
[21]. Similar studies concern the sequential use of im-
munotherapy and targeted treatment using other, not yet 
registered, anti-BRAF/anti-MEK drugs (e.g. the phase 
2 SECOMBIT trial) [22]. It is hoped that the results of 
the mentioned studies will clearly determine the optimal 
order of treatment for patients with unresectable mela-
noma in stage III or IV and mutation in the BRAF gene. 
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